Welcome...
QRxPharma Ltd. (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales. QRxPharma’s lead drug compound, Q8003IR, began Phase III clinical trials in November 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.